Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 43Metastatic Castration-resistant Prostate Cancer 5Prostatic Diseases 3Kidney Neoplasms 3Urogenital Neoplasms 2Prostatic Neoplasms, Castration-Resistant 2Neoplasms by Site 2Neoplasms 2Genital Neoplasms, Male 2Carcinoma, Renal Cell 2Thrombocytopenia 1Renal Insufficiency 1Prostate Cancer Metastatic 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasm Metastasis 1Metastatic Hormone Naive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Metastatic Castration Resistant Prostate Cancer 1Metastatic Castrate Resistant Prostate Cancer (mCRPC) 1Male Urogenital Diseases 1Liver Neoplasms 1High-Risk Localized Prostate Cancer 1Glioma 1Glioblastoma 1Genital Diseases, Male 1Disease 1Cytopenia 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Hepatocellular 1

Interventions

radium Ra 223 dichloride 2pembrolizumab 2enzalutamide 2abiraterone 2Injections 2Abiraterone Acetate 2niraparib 1efineptakin alfa 1darolutamide 1capivasertib 1cabazitaxel 1apalutamide 1Solutions 1Radium-223 1Prednisone 1Pluvicto 1PSMA-11 1Lutetium-177 1Lutetium 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer (mCRPC) × Pluvicto × Clear all
NCT04825652 2023-01-13

177Lu-PSMA-617 Managed Access Program for mCRPC Patients

Advanced Accelerator Applications

No longer available
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡